Alopecia areata treated with efalizumab: A case with significant hair re-growth after long-term therapy

Journal of Drugs in Dermatology

Volumn 8, Issue 8, 2009, Pages 758-760

  Smith, Jeffrey R ^a   Akin, Russell S ^a   Wells, Michael J ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESONIDE; EFALIZUMAB; FLUOCINONIDE; IMIQUIMOD; PREDNISOLONE; TACROLIMUS; TRIAMCINOLONE; MONOCLONAL ANTIBODY;

ALOPECIA AREATA; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CHILD; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECZEMA; HAIR GROWTH; HISPANIC; HUMAN; MALE; OUTCOME ASSESSMENT; SCALP HAIR; SCHOOL CHILD; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; DRUG EFFECT; IMMUNOLOGY; T LYMPHOCYTE; TIME; TREATMENT OUTCOME;

ALOPECIA AREATA; ANTIBODIES, MONOCLONAL; CHILD; DERMATITIS, ATOPIC; HUMANS; MALE; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349242353     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Price V. Therapy of alopecia areata: On the cusp and in the future. J Invest Dermatol Symp Proc. 2008;8(2):207-211.
2. Kaelin U, Hassan A, Braathen L, Yawalkar N. Treatment of alopecia areata partim universalis with efaluzimab. J Am Acad Dermatol. 2006;55(3):529-532. (Pubitemid 44189605)
3. McElwee K, Spiers E, Oliver R, et al. In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol. 1996;135(2):211-217. (Pubitemid 26252968)
4. Moul D, Routhouska S, Robinson M, Korman NJ. Alefacept for moderate to severe atopic dermatitis: A pilot study in adults. J Am Acad Dermatol. 2008;58(6):984-989.
5. Price V, Hordinsky M, Olsen E, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol. 2008;58(3):395-402. (Pubitemid 351226303)
6. Weinberg J, Siegfried E. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch of Dermatol. 2006;142(5):555-558. (Pubitemid 43727544)